Nisa Investment Advisors
BCAX

Nisa Investment Advisors’s Bicara Therapeutics BCAX Stock Holding History

Nisa Investment Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2K Buy
882
+721
+448% +$16.1K ﹤0.01% 2111
2026
Q1 		$3.2K Sell
161
-409
-72% -$7.04K ﹤0.01% 2540
2025
Q4 		$9.59K Buy
570
+409
+254% +$6.99K ﹤0.01% 2245
2025
Q3 		$2.54K Buy
+161
New +$1.8K ﹤0.01% 2573
2025
Q2 		– Sell
-163
Closed -$2.12K – 3108
2025
Q1 		$2.12K Buy
+163
New +$2.17K ﹤0.01% 2452

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nisa Investment Advisors's BCAX Position: Q2 2026 in Review

Nisa Investment Advisors increased its Bicara Therapeutics (BCAX) stake by 448% in Q2 2026, buying an estimated $16.1K and bringing the position to 882 shares worth $26.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2111.

Nisa Investment Advisors first reported a position in BCAX in Q1 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Nisa Investment Advisors held 882 shares of Bicara Therapeutics worth $26.2K as of Q2 2026.
  • Nisa Investment Advisors bought 721 Bicara Therapeutics shares in Q2 2026, an estimated $16.1K.
  • Bicara Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2111 holding.
  • Nisa Investment Advisors first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.